Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Disc Medicine Inc (IRON)

Disc Medicine Inc (IRON)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,677,608
  • Shares Outstanding, K 37,750
  • Annual Sales, $ 0 K
  • Annual Income, $ -109,360 K
  • EBIT $ -204 M
  • EBITDA $ -209 M
  • 60-Month Beta 0.87
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.33

Options Overview Details

View History
  • Implied Volatility 131.40% (+7.12%)
  • Historical Volatility 52.75%
  • IV Percentile 100%
  • IV Rank 100.00%
  • IV High 131.40% on 01/20/26
  • IV Low 40.89% on 09/12/25
  • Expected Move (DTE 31) 17.19 (23.23%)
  • Put/Call Vol Ratio 0.46
  • Today's Volume 41
  • Volume Avg (30-Day) 192
  • Put/Call OI Ratio 0.99
  • Today's Open Interest 3,459
  • Open Int (30-Day) 2,246
  • Expected Range 56.81 to 91.19

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.71
  • Number of Estimates 9
  • High Estimate -1.51
  • Low Estimate -1.87
  • Prior Year -0.98
  • Growth Rate Est. (year over year) -74.49%

Price Performance

See More
Period Period Low Period High Performance
1-Month
69.17 +6.98%
on 01/20/26
81.90 -9.65%
on 01/08/26
-6.04 (-7.55%)
since 12/19/25
3-Month
69.17 +6.98%
on 01/20/26
99.50 -25.63%
on 12/08/25
-13.17 (-15.11%)
since 10/20/25
52-Week
30.82 +140.10%
on 04/09/25
99.50 -25.63%
on 12/08/25
+15.76 (+27.05%)
since 01/17/25

Most Recent Stories

More News
Disc Medicine Appoints Lisa Amaya Price, MBA as Chief Human Resources Officer

WATERTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...

IRON : 74.00 (+4.33%)
Disc Medicine Highlights Recent Achievements and Key Business Objectives and Milestones for 2026

Bitopertin was awarded the Commissioner’s National Priority Review Voucher (CNPV) and NDA is currently under FDA review Updated data from the Phase 2 study of DISC-0974 in patients with myelofibrosis...

IRON : 74.00 (+4.33%)
Disc Medicine to Present at the 44th Annual J.P. Morgan Healthcare Conference

WATERTOWN, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...

IRON : 74.00 (+4.33%)
Disc Medicine Presents Positive Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting

Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status  Anemia response was seen independent of concomitant JAK inhibitor therapy use...

IRON : 74.00 (+4.33%)
Disc Medicine Reports Third Quarter 2025 Financial Results and Provides Business Update

Submitted a New Drug Application (NDA) for accelerated approval of bitopertin in erythropoietic protoporphyria (EPP) on September 29, 2025; Awarded the FDA Commissioner’s National Priority Voucher (CNPV),...

IRON : 74.00 (+4.33%)
Disc Medicine Announces Presentation of Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting

WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...

IRON : 74.00 (+4.33%)
Disc Medicine to Participate in Upcoming Investor Conferences

WATERTOWN, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...

IRON : 74.00 (+4.33%)
Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

WATERTOWN, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization...

IRON : 74.00 (+4.33%)
Disc Medicine to Present Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2025 American Society of Nephrology (ASN) Kidney Week

WATERTOWN, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...

IRON : 74.00 (+4.33%)
Disc Medicine Announces Receipt of FDA Commissioner’s National Priority Voucher (CNPV) for Bitopertin in Erythropoietic Protoporphyria (EPP)

Disc is seeking accelerated approval of bitopertin for patients aged 12 years and older with EPP The CNPV program is designed to reduce the drug application review process to 1-2 months WATERTOWN,...

IRON : 74.00 (+4.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Disc Medicine Inc. is a clinical-stage biopharmaceutical company. It focused on the discovery and development of novel treatments for patients suffering from serious hematologic diseases. Disc Medicine Inc., formerly known as Gemini Therapeutics Inc., is based in WAYLAND, Mass.

See More

Key Turning Points

3rd Resistance Point 80.57
2nd Resistance Point 77.33
1st Resistance Point 75.66
Last Price 74.00
1st Support Level 70.75
2nd Support Level 67.51
3rd Support Level 65.84

See More

52-Week High 99.50
Last Price 74.00
Fibonacci 61.8% 73.26
Fibonacci 50% 65.16
Fibonacci 38.2% 57.06
52-Week Low 30.82

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar